Valuation: PuraPharm Corporation Limited

Market Cap 150M 19.1M 16.59M 15.41M 14.21M 26.76M 1.82B 27.25M 182M 71.42M 906M 71.73M 70.16M 3.05B P/E 2024
-6.13x
P/E 2025 -4.22x
Enterprise Value 465M 59.29M 51.5M 47.83M 44.11M 83.09M 5.66B 84.59M 566M 222M 2.81B 223M 218M 9.45B EV / Sales 2024
1.42x
EV / Sales 2025 1.5x
Free-Float
34.74%
Yield 2024 *
-
Yield 2025 -
06-25 Purapharm Corporation Limited Announces Resignation of Prof. Tsui Lap Chee from Independent Non-Executive Director and Board Committees, Effective June 25, 2026 CI
04-27 PuraPharm Corporation Limited Announces Appointment of Lee Stephen as Independent Non-Executive Director, Effective April 27, 2026 CI
04-22 PuraPharm Corporation Limited Auditor Raises 'Going Concern' Doubt CI
03-26 PuraPharm's Loss Narrows Slightly in 2025 MT
03-25 PuraPharm Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-24 PuraPharm Completes HK$20 Million Convertible Bond Issue MT
03-22 PuraPharm Corporation Limited announced that it has received HKD 20 million in funding from Protoss Global Opportunities Fund CI
02-26 Purapharm Corp to issue convertible bonds with principal amount of HK$20 mln RE
02-26 PuraPharm Sells HK$20 Million Convertible Bonds MT
02-25 PuraPharm Corporation Limited announced that it expects to receive HKD 20 million in funding from Protoss Global Opportunities Fund CI
30/10/25 PuraPharm Corporation Limited Announces Appointment of Dong Zimeng as Non-Executive Director, Effective October 30, 2025 CI
02/10/25 PuraPharm to Vote Oct. 24 on Rheumatoid Arthritis Drug License, Share Issue Agreements MT
29/08/25 Purapharm Corporation Limited Appoints Hung Ting On, John as Independent Non-Executive Director, the Chairman of the Audit Committee of the Board, the Member of the Remuneration Committee of the Board and Member of Nomination Committee of the Board, Effective August 29, 2025 CI
1 day+1.82%
1 week-1.75%
Current month-5.08%
1 month-5.08%
3 months-3.45%
6 months-17.65%
Current year-21.13%
1 week 0.27
Extreme 0.27
0.3
1 month 0.27
Extreme 0.27
0.3
Current year 0.27
Extreme 0.27
0.38
1 year 0.27
Extreme 0.27
0.48
3 years 0.27
Extreme 0.27
1.26
5 years 0.27
Extreme 0.27
2
10 years 0.27
Extreme 0.27
4.39
Manager TitleAgeSince
Chief Executive Officer 65 04/05/1998
Director of Finance/CFO 38 31/12/2023
Investor Relations Contact - -
Director TitleAgeSince
Chairman 65 04/05/1998
Director/Board Member 60 01/12/2011
Director/Board Member 72 11/06/2015
Date Insider Type Main position Quantity % Market Cap.
27/07/22 Other

Chief Executive Officer

30,000 0.0076%
27/07/22 Other 30,000 0.0076%
03/05/22 Other

Chief Executive Officer

77,500 0.0196%
Change 5-day change 1-year change 3-year change Capi.($)
+1.82%-1.75%-41.67%-72.28% 18.76M
0.00%-0.48%+25.94%+41.77% 18.04B
-0.34%+1.07%+20.23%+67.52% 13.54B
0.00%+3.65%-31.00%-55.20% 12.44B
-0.69%-2.54%-0.08%+66.62% 11B
-1.37%+1.87%+17.49%+81.92% 10.34B
+1.05%0.00%-11.52%-33.22% 9.04B
-0.41%+0.14%+12.14%+181.88% 7.5B
+0.34%+4.75%+14.04%-23.11% 7.12B
+1.80%+1.35%-24.67% - 6.72B
Average +0.24%+2.00%-1.91%+28.43% 9.58B
Weighted average by Cap. -0.03%+2.19%+4.77%+38.84%

Financials

2024 2025
Net sales 382M 48.72M 42.31M 39.29M 36.24M 68.26M 4.65B 69.5M 465M 182M 2.31B 183M 179M 7.77B 336M 42.85M 37.22M 34.57M 31.88M 60.05M 4.09B 61.14M 409M 160M 2.03B 161M 157M 6.83B
Net income -35.44M -4.52M -3.92M -3.64M -3.36M -6.33M -431M -6.45M -43.15M -16.89M -214M -16.97M -16.6M -720M -35.22M -4.49M -3.9M -3.62M -3.34M -6.29M -429M -6.41M -42.88M -16.79M -213M -16.86M -16.5M -716M
Net Debt 327M 41.67M 36.2M 33.61M 31M 58.4M 3.98B 59.45M 398M 156M 1.98B 157M 153M 6.65B 315M 40.19M 34.91M 32.42M 29.9M 56.32M 3.84B 57.34M 384M 150M 1.91B 151M 148M 6.41B
Logo PuraPharm Corporation Limited
PuraPharm Corporation Ltd is an investment holding company principally engaged in the concentrated Chinese medicine granule (CCMG) businesses. The Company operates through five business segments. The China CCMG segment is mainly engaged in the production and sales of CCMG products in China. The Hong Kong CCMG segment is mainly engaged in the sales of CCMG products, excluding the sales through self-operated clinics in Hong Kong. The Chinese Healthcare Products segment is mainly engaged in the production and sales of healthcare products in Hong Kong and China. The Clinics segment is mainly engaged in the provision of Chinese medical diagnostic services and sales of CCMG products through self-operated clinics. The Plantation segment is mainly engaged in the plantation and trading of raw Chinese herbs, and the manufacture and sale of traditional Chinese medicine (TCM) decoction pieces.
Employees
441
Date Price Change Volume
31/07/26 HK$0.2800 +1.82% 41,000
30/07/26 HK$0.2750 -3.51% 308,000
29/07/26 HK$0.2850 -1.72% 56,500
28/07/26 HK$0.2900 0.00% 168,000
27/07/26 HK$0.2900 +1.75% 52,500

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 1498 Stock